StockIQ.techArvinas, Inc. (ARVN) Stock Analysis
Free AI-powered analysis and research for Arvinas, Inc. stock
Sector: Healthcare
Full ARVN report
Arvinas, Inc. (ARVN) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze ARVN Now →📰 Latest Update
What Arvinas (ARVN) Said on Its Q3 Earnings Call
Tue, November 3, 2026 at 3:14 PM UTC 3 min read
Arvinas (NASDAQ: ARVN) highlighted key clinical milestones during its Q3 2026 earnings call, reporting lower operating expenses and a cash runway extending into the second half of 2028. The company plans to present initial data on T-cell lymphoma patients at the upcoming ASH conference and is advancing its neurology programs, including a Phase I trial for ARV-027 targeting spinal bulbar muscular atrophy. Additionally, Arvinas initiated a Phase I trial for ARV-6723, an oral HPK1 degrader, with initial clinical data expected in late 2027.